Notice of Diabetes Mellitus Interagency Coordinating Committee Meeting, 25459-25460 [2013-10307]
Download as PDF
Federal Register / Vol. 78, No. 84 / Wednesday, May 1, 2013 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Cancer
Therapy (Omnibus).
Date: June 27–28, 2013.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel &
Conference Center, 5701 Marinelli Road,
North Bethesda, MD 20852.
Contact Person: Caron A Lyman, Ph.D.,
Scientific Review Officer, National Cancer
Institute, Division of Extramural Activities,
Research Programs Review Branch, 9609
Medical Center Dr., Rm 7W412, Bethesda,
MD 20892–975, 240–276–6348,
lymanc@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: April 25, 2013.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–10199 Filed 4–30–13; 8:45 am]
BILLING CODE 4140–01–P
wreier-aviles on DSK5TPTVN1PROD with NOTICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meeting
14:21 Apr 30, 2013
Jkt 229001
Name of Committee: National Cancer
Institute Special Emphasis Panel; National
Clinical Trial Network Groups.
Date: July 16–17, 2013.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Washington/Rockville, 1750
Rockville Pike, Rockville, MD 20852.
Contact Person: Shamala K. Srinivas,
Ph.D., Scientific Review Officer, National
Cancer Institute, Division of Extramural
Activities, Research Programs Review
Branch, 9609 Medical Center Dr., Room
7W530, Bethesda, MD 20892–975, 240–276–
6442 ss537t@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: April 25, 2013.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–10200 Filed 4–30–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Notice of Diabetes Mellitus Interagency
Coordinating Committee Meeting
SUMMARY: The Diabetes Mellitus
Interagency Coordinating Committee
(DMICC) will hold a meeting on May 23,
2013 from 1:00 to 3:30 p.m. at the Lister
Hill Center Auditorium (Building 38A),
National Library of Medicine, on the
NIH Campus at 8600 Rockville Pike,
Bethesda, MD 20894. The meeting is
open to the public.
The meeting will be held on May
23, 2013 from 1:00 to 3:30 p.m.
Individuals wanting to present oral
comments must notify the contact
person at least 10 days before the
meeting date.
DATES:
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
VerDate Mar<15>2010
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
25459
The meeting will be held at
the Lister Hill Center Auditorium
(Building 38A), National Library of
Medicine, on the NIH Campus at 8600
Rockville Pike, Bethesda, MD 20894.
ADDRESSES:
For
further information concerning this
meeting, see the DMICC Web site,
www.diabetescommittee.gov, or contact
Dr. B. Tibor Roberts, Executive
Secretary of the Diabetes Mellitus
Interagency Coordinating Committee,
National Institute of Diabetes and
Digestive and Kidney Diseases, 31
Center Drive, Building 31A, Room
9A19, MSC 2560, Bethesda, MD 20892–
2560, telephone: 301–496–6623; FAX:
301–480–6741; email:
dmicc@mail.nih.gov.
FOR FURTHER INFORMATION CONTACT:
The
DMICC, chaired by the National
Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK) comprising
members of the Department of Health
and Human Services and other federal
agencies that support diabetes-related
activities, facilitates cooperation,
communication, and collaboration on
diabetes among government entities.
DMICC meetings, held several times a
year, provide an opportunity for
Committee members to learn about and
discuss current and future diabetes
programs in DMICC member
organizations and to identify
opportunities for collaboration. The
May 23, 2013 DMICC meeting will focus
on ‘‘Long-term Outcomes of Bariatric
Surgery.’’
Any member of the public interested
in presenting oral comments to the
Committee should notify the contact
person listed on this notice at least 10
days in advance of the meeting.
Interested individuals and
representatives or organizations should
submit a letter of intent, a brief
description of the organization
represented, and a written copy of their
oral presentation in advance of the
meeting. Only one representative of an
organization will be allowed to present;
oral comments and presentations will be
limited to a maximum of 5 minutes.
Printed and electronic copies are
requested for the record. In addition,
any interested person may file written
comments with the Committee by
forwarding their statement to the
contact person listed on this notice. The
statement should include the name,
address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Because of time constraints for the
meeting, oral comments will be allowed
on a first-come, first-serve basis.
SUPPLEMENTARY INFORMATION:
E:\FR\FM\01MYN1.SGM
01MYN1
25460
Federal Register / Vol. 78, No. 84 / Wednesday, May 1, 2013 / Notices
Members of the public who would
like to receive email notification about
future DMICC meetings should register
for the listserv available on the DMICC
Web site, www.diabetescommittee.gov.
Dated: April 25, 2013.
B. Tibor Roberts,
Executive Secretary, DMICC, Office of
Scientific Program and Policy Analysis,
National Institute of Diabetes and Digestive
and Kidney Diseases, National Institutes of
Health.
MSC 7840, Bethesda, MD 20892, 301–435–
1256, harwoodj@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: April 25, 2013.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–10307 Filed 4–30–13; 8:45 am]
[FR Doc. 2013–10198 Filed 4–30–13; 8:45 am]
BILLING CODE 4140–01–P
BILLING CODE 4140–01–P
Contact Person: Nadine Rogers, Ph.D.,
Scientific Review Officer, Office of
Extramural Affairs, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive
Blvd., Room 4229, MSC 9550, Bethesda, MD
20892–9550, 301–402–2105,
rogersn2@nida.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos.: 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: April 25, 2013.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–10202 Filed 4–30–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Center for Scientific Review; Notice of
Closed Meetings
National Institute on Drug Abuse;
Notice of Closed Meetings
National Institutes of Health
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
wreier-aviles on DSK5TPTVN1PROD with NOTICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Name of Committee: Center for Scientific
Review Special Emphasis Panel
Member Conflict: Cardiovascular
Epidemiology and Infectious Disease.
Date: May 28, 2013.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Mary Ann Guadagno,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3170,
MSC 7770, Bethesda, MD 20892, (301) 451–
8011, guadagma@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel
Member Conflict: Eye Diseases #4.
Date: May 28, 2013.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: James P Harwood, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5168,
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable materials,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIDA
I/START Small Grant Review.
Date: June 19, 2013.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Virtual
Meeting).
Contact Person: Gerald L. McLaughlin,
Ph.D., Scientific Review Officer, Office of
Extramural Affairs, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive
Blvd., Room 4238, MSC 9550, Bethesda, MD
20892–9550, 301–402–6626,
gm145a@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; Cohort
Studies of HIV/AIDS and Substance Abuse
(U01).
Date: July 17, 2013.
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Telephone
Conference Call).
VerDate Mar<15>2010
14:21 Apr 30, 2013
Jkt 229001
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 USC,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable materials,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Biomarker Study for Creatine Transporter
Defect Disorders (Topic 002, SBIR Phase I,
NCATS).
Date: May 14, 2013.
Time: 10:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Telephone
Conference Call).
Contact Person: Lyle Furr, Scientific
Review Officer, Office of Extramural Affairs,
National Institute on Drug Abuse, NIH,
DHHS, Room 4227, MSC 9550, 6001
Executive Boulevard, Bethesda, MD 20892–
9550, (301) 435–1439, lf33c@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; SBIR
Phase II Contract Review—Recovery Warrior:
Behavioral Activation Video Game for
Substance Abuse (Topic 141).
Date: May 20, 2013.
Time: 2:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate contract
proposals.
E:\FR\FM\01MYN1.SGM
01MYN1
Agencies
[Federal Register Volume 78, Number 84 (Wednesday, May 1, 2013)]
[Notices]
[Pages 25459-25460]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-10307]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Notice of Diabetes Mellitus Interagency Coordinating Committee
Meeting
SUMMARY: The Diabetes Mellitus Interagency Coordinating Committee
(DMICC) will hold a meeting on May 23, 2013 from 1:00 to 3:30 p.m. at
the Lister Hill Center Auditorium (Building 38A), National Library of
Medicine, on the NIH Campus at 8600 Rockville Pike, Bethesda, MD 20894.
The meeting is open to the public.
DATES: The meeting will be held on May 23, 2013 from 1:00 to 3:30 p.m.
Individuals wanting to present oral comments must notify the contact
person at least 10 days before the meeting date.
ADDRESSES: The meeting will be held at the Lister Hill Center
Auditorium (Building 38A), National Library of Medicine, on the NIH
Campus at 8600 Rockville Pike, Bethesda, MD 20894.
FOR FURTHER INFORMATION CONTACT: For further information concerning
this meeting, see the DMICC Web site, www.diabetescommittee.gov, or
contact Dr. B. Tibor Roberts, Executive Secretary of the Diabetes
Mellitus Interagency Coordinating Committee, National Institute of
Diabetes and Digestive and Kidney Diseases, 31 Center Drive, Building
31A, Room 9A19, MSC 2560, Bethesda, MD 20892-2560, telephone: 301-496-
6623; FAX: 301-480-6741; email: dmicc@mail.nih.gov.
SUPPLEMENTARY INFORMATION: The DMICC, chaired by the National Institute
of Diabetes and Digestive and Kidney Diseases (NIDDK) comprising
members of the Department of Health and Human Services and other
federal agencies that support diabetes-related activities, facilitates
cooperation, communication, and collaboration on diabetes among
government entities. DMICC meetings, held several times a year, provide
an opportunity for Committee members to learn about and discuss current
and future diabetes programs in DMICC member organizations and to
identify opportunities for collaboration. The May 23, 2013 DMICC
meeting will focus on ``Long-term Outcomes of Bariatric Surgery.''
Any member of the public interested in presenting oral comments to
the Committee should notify the contact person listed on this notice at
least 10 days in advance of the meeting. Interested individuals and
representatives or organizations should submit a letter of intent, a
brief description of the organization represented, and a written copy
of their oral presentation in advance of the meeting. Only one
representative of an organization will be allowed to present; oral
comments and presentations will be limited to a maximum of 5 minutes.
Printed and electronic copies are requested for the record. In
addition, any interested person may file written comments with the
Committee by forwarding their statement to the contact person listed on
this notice. The statement should include the name, address, telephone
number and when applicable, the business or professional affiliation of
the interested person. Because of time constraints for the meeting,
oral comments will be allowed on a first-come, first-serve basis.
[[Page 25460]]
Members of the public who would like to receive email notification
about future DMICC meetings should register for the listserv available
on the DMICC Web site, www.diabetescommittee.gov.
Dated: April 25, 2013.
B. Tibor Roberts,
Executive Secretary, DMICC, Office of Scientific Program and Policy
Analysis, National Institute of Diabetes and Digestive and Kidney
Diseases, National Institutes of Health.
[FR Doc. 2013-10307 Filed 4-30-13; 8:45 am]
BILLING CODE 4140-01-P